{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T17:54:55Z","timestamp":1769018095263,"version":"3.49.0"},"reference-count":42,"publisher":"e-Century Publishing Corporation","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Cancer Res"],"DOI":"10.62347\/vngo9832","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T07:28:01Z","timestamp":1764314881000},"page":"4753-4764","source":"Crossref","is-referenced-by-count":0,"title":["Comparative effectiveness of paclitaxel versus cyclophosphamide in platinum-based adjuvant treatment of high-risk early-stage epithelial ovarian cancer: an Asian population study"],"prefix":"10.62347","volume":"15","author":[{"given":"Mei-Yi","family":"Lin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"48694","published-online":{"date-parts":[[2025]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1007\/s00261-021-03081-0","article-title":"Current update on malignant epithelial ovarian tumors","volume":"46","author":"Elsherif","year":"2021","unstructured":"Elsherif SB, Bhosale PR, Lall C, Menias CO, Itani M, Butler KA and Ganeshan D. Current update on malignant epithelial ovarian tumors. Abdom Radiol (NY) 2021; 46: 2264-2280.","journal-title":"Abdom Radiol (NY)"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s00428-012-1203-5","article-title":"Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features","volume":"460","author":"Prat","year":"2012","unstructured":"Prat J. Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features. Virchows Arch 2012; 460: 237-249.","journal-title":"Virchows Arch"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.ygyno.2009.10.074","article-title":"Survival after recurrence in early-stage high-risk epithelial ovarian cancer: a Gynecologic Oncology Group study","volume":"116","author":"Chan","year":"2010","unstructured":"Chan JK, Tian C, Teoh D, Monk BJ, Herzog T, Kapp DS and Bell J. Survival after recurrence in early-stage high-risk epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol 2010; 116: 307-311.","journal-title":"Gynecol Oncol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"5627","DOI":"10.3390\/jcm11195627","article-title":"Epidemiology and mortality of ovarian cancer in Taiwan: a population-based study","volume":"11","author":"Teng","year":"2022","unstructured":"Teng YH, Liu FC, Huang SY, Kuo CF and Yu HP. Epidemiology and mortality of ovarian cancer in Taiwan: a population-based study. J Clin Med 2022; 11: 5627.","journal-title":"J Clin Med"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.bpobgyn.2016.10.001","article-title":"Surgical treatment of early-stage ovarian cancer","volume":"41","author":"Trimbos","year":"2017","unstructured":"Trimbos JB. Surgical treatment of early-stage ovarian cancer. Best Pract Res Clin Obstet Gynaecol 2017; 41: 60-70.","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1093\/jnci\/95.2.125","article-title":"International collaborative ovarian neoplasm trial 1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer","volume":"95","author":"Colombo","year":"2003","unstructured":"Colombo N, Guthrie D, Chiari S, Parmar M, Qian W, Swart AM, Torri V, Williams C, Lissoni A and Bonazzi C; International Collaborative Ovarian Neoplasm (ICON) collaborators. International collaborative ovarian neoplasm trial 1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer. J Natl Cancer Inst 2003; 95: 125-132.","journal-title":"J Natl Cancer Inst"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1093\/jnci\/95.2.113","article-title":"Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European organisation for research and treatment of cancer-adjuvant chemotherapy in ovarian neoplasm trial","volume":"95","author":"JB","year":"2003","unstructured":"Trimbos JB, Vergote I, Bolis G, Vermorken JB, Mangioni C, Madronal C, Franchi M, Tateo S, Zanetta G, Scarfone G, Giurgea L, Timmers P, Coens C and Pecorelli S; EORTC-ACTION collaborators. European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European organisation for research and treatment of cancer-adjuvant chemotherapy in ovarian neoplasm trial. J Natl Cancer Inst 2003; 95: 113-125.","journal-title":"J Natl Cancer Inst"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1093\/jnci\/92.9.699","article-title":"Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results","volume":"92","author":"Piccart","year":"2000","unstructured":"Piccart MJ, Bertelsen K, James K, Cassidy J, Mangioni C, Simonsen E, Stuart G, Kaye S, Vergote I, Blom R, Grimshaw R, Atkinson RJ, Swenerton KD, Trope C, Nardi M, Kaern J, Tumolo S, Timmers P, Roy JA, Lhoas F, Lindvall B, Bacon M, Birt A, Andersen JE, Zee B, Paul J, Baron B and Pecorelli S. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 2000; 92: 699-708.","journal-title":"J Natl Cancer Inst"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1056\/NEJM199601043340101","article-title":"Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer","volume":"334","author":"McGuire","year":"1996","unstructured":"McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL and Davidson M. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996; 334: 1-6.","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.ygyno.2006.06.013","article-title":"Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study","volume":"102","author":"Bell","year":"2006","unstructured":"Bell J, Brady MF, Young RC, Lage J, Walker JL, Look KY, Rose GS and Spirtos NM; Gynecologic Oncology Group. Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2006; 102: 432-439.","journal-title":"Gynecol Oncol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1097\/IGC.0b013e3182070f17","article-title":"1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG)","volume":"21","author":"GJ","year":"2011","unstructured":"Rustin GJ, Vergote I, Eisenhauer E, Pujade-Lauraine E, Quinn M, Thigpen T, du Bois A, Kristensen G, Jakobsen A, Sagae S, Greven K, Parmar M, Friedlander M, Cervantes A and Vermorken J; Gynecological Cancer Intergroup. Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG). Int J Gynecol Cancer 2011; 21: 419-423.","journal-title":"Int J Gynecol Cancer"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1056\/NEJM199004123221501","article-title":"Results of two prospective randomized trials","volume":"322","author":"Young","year":"1990","unstructured":"Young RC, Walton LA, Ellenberg SS, Homesley HD, Wilbanks GD, Decker DG, Miller A, Park R and Major F Jr. Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials. N Engl J Med 1990; 322: 1021-1027.","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1002\/1097-0142(19860501)57:9<1725::AID-CNCR2820570903>3.0.CO;2-J","article-title":"A Gynecologic Oncology Group Study","volume":"57","author":"Omura","year":"1986","unstructured":"Omura G, Blessing JA, Ehrlich CE, Miller A, Yordan E, Creasman WT and Homesley HD. A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A Gynecologic Oncology Group Study. Cancer 1986; 57: 1725-1730.","journal-title":"Cancer"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1111\/j.1445-5994.1982.tb02469.x","article-title":"Advanced ovarian cancer: a prospective randomised trial of chlorambucil versus combined cyclophosphamide and cis-diamminedichloroplatinum","volume":"12","author":"Bell","year":"1982","unstructured":"Bell DR, Woods RL, Levi JA, Fox RM and Tattersall MH. Advanced ovarian cancer: a prospective randomised trial of chlorambucil versus combined cyclophosphamide and cis-diamminedichloroplatinum. Aust N Z J Med 1982; 12: 245-249.","journal-title":"Aust N Z J Med"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/0090-8258(87)90210-1","article-title":"A randomized study of cyclophosphamide and cis-platinum with or without doxorubicin in advanced ovarian carcinoma","volume":"28","author":"Bertelsen","year":"1987","unstructured":"Bertelsen K, Jakobsen A, Andersen JE, Ahrons S, Pedersen PH, Kiaer H, Arffmann E, Bichel P, Boestofte E, Str&#xF8;yer I, et al. A randomized study of cyclophosphamide and cis-platinum with or without doxorubicin in advanced ovarian carcinoma. Gynecol Oncol 1987; 28: 161-169.","journal-title":"Gynecol Oncol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1200\/JCO.1989.7.4.457","article-title":"Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a Gynecologic Oncology Group Study","volume":"7","author":"Omura","year":"1989","unstructured":"Omura GA, Bundy BN, Berek JS, Curry S, Delgado G and Mortel R. Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 1989; 7: 457-465.","journal-title":"J Clin Oncol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"4350","DOI":"10.1200\/JCO.2003.02.154","article-title":"Adjuvant treatment for early ovarian cancer: a randomized phase III trial of intraperitoneal 32P or intravenous cyclophosphamide and cisplatin--a gynecologic oncology group study","volume":"21","author":"Young","year":"2003","unstructured":"Young RC, Brady MF, Nieberg RK, Long HJ, Mayer AR, Lentz SS, Hurteau J and Alberts DS. Adjuvant treatment for early ovarian cancer: a randomized phase III trial of intraperitoneal 32P or intravenous cyclophosphamide and cisplatin--a gynecologic oncology group study. J Clin Oncol 2003; 21: 4350-4355.","journal-title":"J Clin Oncol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1093\/annonc\/mdl400","article-title":"Carboplatin\/cyclophosphamide or carboplatin\/paclitaxel in elderly patients with advanced ovarian cancer? Analysis of two consecutive trials from the Groupe d&#x2019;Investigateurs Nationaux pour l&#x2019;Etude des Cancers Ovariens","volume":"18","author":"Tr&#xE9","year":"2007","unstructured":"Tr&#xE9;dan O, Geay JF, Touzet S, Delva R, Weber B, Cretin J, Provencal J, Martin J, Stefani L, Pujade-Lauraine E and Freyer G; Groupe d&#x2019;Investigateurs Nationaux pour l&#x2019;Etude des Cancers Ovariens. Carboplatin\/cyclophosphamide or carboplatin\/paclitaxel in elderly patients with advanced ovarian cancer? Analysis of two consecutive trials from the Groupe d&#x2019;Investigateurs Nationaux pour l&#x2019;Etude des Cancers Ovariens. Ann Oncol 2007; 18: 256-262.","journal-title":"Ann Oncol"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Chen CA, Chiang CJ, Chen YY, You SL, Hsieh SF, Tang CH and Cheng WF. Survival benefit of patients with early-stage ovarian carcinoma treated with paclitaxel chemotherapeutic regimens. J Gynecol Oncol 2018; 29: e16.","DOI":"10.3802\/jgo.2018.29.e16"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Garc&#xED;a-S&#xE1;enz JA, Custodio A, Casado A, Vidart JA, Coronado PJ, Mart&#xED;n M, L&#xF3;pez-Tarruella S, Puente J, Fern&#xE1;ndez C and D&#xED;az-Rubio E. Platinum-based adjuvant chemotherapy on moderate- and high-risk stage I and II epithelian ovarian cancer patients. Long-term single institution experience and literature review. Clin Transl Oncol 2011; 13: 121-132.","DOI":"10.1007\/s12094-011-0629-6"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"637","DOI":"10.3390\/ijerph16040637","article-title":"Prognostic factors of early stage epithelial ovarian carcinoma","volume":"16","author":"Hsieh","year":"2019","unstructured":"Hsieh SF, Lau HY, Wu HH, Hsu HC, Twu NF and Cheng WF. Prognostic factors of early stage epithelial ovarian carcinoma. Int J Environ Res Public Health 2019; 16: 637.","journal-title":"Int J Environ Res Public Health"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"216057","DOI":"10.1016\/j.canlet.2023.216057","article-title":"Molecular characteristics and clinical behaviour of epithelial ovarian cancers","volume":"555","author":"Hollis","year":"2023","unstructured":"Hollis RL. Molecular characteristics and clinical behaviour of epithelial ovarian cancers. Cancer Lett 2023; 555: 216057.","journal-title":"Cancer Lett"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/nm0196-72","article-title":"Loss of normal p53 function confers sensitization to Taxol by increasing G2\/M arrest and apoptosis","volume":"2","author":"Wahl","year":"1996","unstructured":"Wahl AF, Donaldson KL, Fairchild C, Lee FY, Foster SA, Demers GW and Galloway DA. Loss of normal p53 function confers sensitization to Taxol by increasing G2\/M arrest and apoptosis. Nat Med 1996; 2: 72-79.","journal-title":"Nat Med"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"18824","DOI":"10.3390\/ijms140918824","article-title":"ARID1A mutations and PI3K\/AKT pathway alterations in endometriosis and endometriosis-associated ovarian carcinomas","volume":"14","author":"Samartzis","year":"2013","unstructured":"Samartzis EP, Noske A, Dedes KJ, Fink D and Imesch P. ARID1A mutations and PI3K\/AKT pathway alterations in endometriosis and endometriosis-associated ovarian carcinomas. Int J Mol Sci 2013; 14: 18824-18849.","journal-title":"Int J Mol Sci"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"573","DOI":"10.20517\/cdr.2021.05","article-title":"Targeting the PI3K\/AKT\/mTOR pathway in epithelial ovarian cancer, therapeutic treatment options for platinum-resistant ovarian cancer","volume":"4","author":"Rinne","year":"2021","unstructured":"Rinne N, Christie EL, Ardasheva A, Kwok CH, Demchenko N, Low C, Tralau-Stewart C, Fotopoulou C and Cunnea P. Targeting the PI3K\/AKT\/mTOR pathway in epithelial ovarian cancer, therapeutic treatment options for platinum-resistant ovarian cancer. Cancer Drug Resist 2021; 4: 573-595.","journal-title":"Cancer Drug Resist"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa1008433","article-title":"ARID1A mutations in endometriosis-associated ovarian carcinomas","volume":"363","author":"Wiegand","year":"2010","unstructured":"Wiegand KC, Shah SP, Al-Agha OM, Zhao Y, Tse K, Zeng T, Senz J, McConechy MK, Anglesio MS, Kalloger SE, Yang W, Heravi-Moussavi A, Giuliany R, Chow C, Fee J, Zayed A, Prentice L, Melnyk N, Turashvili G, Delaney AD, Madore J, Yip S, McPherson AW, Ha G, Bell L, Fereday S, Tam A, Galletta L, Tonin PN, Provencher D, Miller D, Jones SJ, Moore RA, Morin GB, Oloumi A, Boyd N, Aparicio SA, Shih IeM, Mes-Masson AM, Bowtell DD, Hirst M, Gilks B, Marra MA and Huntsman DG. ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med 2010; 363: 1532-1543.","journal-title":"N Engl J Med"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1002\/1878-0261.13679","article-title":"Endometrioid ovarian carcinoma landscape: pathological and molecular characterization","volume":"18","author":"Nonneville A","year":"2024","unstructured":"de Nonneville A, Kalbacher E, Cannone F, Guille A, Adela&#xEF;de J, Finetti P, Cappiello M, Lambaudie E, Ettore G, Charafe E, Mamessier E, Provansal M, Bertucci F and Sabatier R. Endometrioid ovarian carcinoma landscape: pathological and molecular characterization. Mol Oncol 2024; 18: 2586-2600.","journal-title":"Mol Oncol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1038\/nrd3253","article-title":"Microtubule-binding agents: a dynamic field of cancer therapeutics","volume":"9","author":"Dumontet","year":"2010","unstructured":"Dumontet C and Jordan MA. Microtubule-binding agents: a dynamic field of cancer therapeutics. Nat Rev Drug Discov 2010; 9: 790-803.","journal-title":"Nat Rev Drug Discov"},{"key":"ref28","unstructured":"Hu L, Hofmann J, Lu Y, Mills GB and Jaffe RB. Inhibition of phosphatidylinositol 3&#x2019;-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Cancer Res 2002; 62: 1087-1092."},{"key":"ref29","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1038\/nrclinonc.2009.146","article-title":"Cyclophosphamide and cancer: golden anniversary","volume":"6","author":"Emadi","year":"2009","unstructured":"Emadi A, Jones RJ and Brodsky RA. Cyclophosphamide and cancer: golden anniversary. Nat Rev Clin Oncol 2009; 6: 638-647.","journal-title":"Nat Rev Clin Oncol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1002\/jcc.27280","article-title":"Insights on cyclophosphamide metabolism and anticancer mechanism of action: a computational study","volume":"45","author":"Dabbish","year":"2024","unstructured":"Dabbish E, Scoditti S, Shehata MNI, Ritacco I, Ibrahim MAA, Shoeib T and Sicilia E. Insights on cyclophosphamide metabolism and anticancer mechanism of action: a computational study. J Comput Chem 2024; 45: 663-670.","journal-title":"J Comput Chem"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"665","DOI":"10.2165\/00003088-200342070-00005","article-title":"Pharmacological effects of formulation vehicles: implications for cancer chemotherapy","volume":"42","author":"ten Tije","year":"2003","unstructured":"ten Tije AJ, Verweij J, Loos WJ and Sparreboom A. Pharmacological effects of formulation vehicles: implications for cancer chemotherapy. Clin Pharmacokinet 2003; 42: 665-685.","journal-title":"Clin Pharmacokinet"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s13048-016-0247-6","article-title":"High levels of pretreatment CA125 are associated to improved survival in high grade serous ovarian carcinoma","volume":"9","author":"Morales-V&#xE1","year":"2016","unstructured":"Morales-V&#xE1;squez F, Pedernera E, Reynaga-Obreg&#xF3;n J, L&#xF3;pez-Basave HN, G&#xF3;mora MJ, Carl&#xF3;n E, C&#xE1;rdenas S, Silva-Ayala R, Almaraz M and M&#xE9;ndez C. High levels of pretreatment CA125 are associated to improved survival in high grade serous ovarian carcinoma. J Ovarian Res 2016; 9: 41.","journal-title":"J Ovarian Res"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1186\/s12885-021-08061-7","article-title":"Clinical characteristics and prognosis of ovarian clear cell carcinoma: a 10-year retrospective study","volume":"21","author":"Zhu","year":"2021","unstructured":"Zhu C, Zhu J, Qian L, Liu H, Shen Z, Wu D, Zhao W, Xiao W and Zhou Y. Clinical characteristics and prognosis of ovarian clear cell carcinoma: a 10-year retrospective study. BMC Cancer 2021; 21: 322.","journal-title":"BMC Cancer"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1006\/gyno.2000.5982","article-title":"Prognostic significance of CA 125 and TPS levels after 3 chemotherapy courses in ovarian cancer patients","volume":"79","author":"van Dalen","year":"2000","unstructured":"van Dalen A, Favier J, Burges A, Hasholzner U, de Bruijn HW, Dobler-Girdziunaite D, Dombi VH, Fink D, Giai M, McGing P, Harlozinska A, Kainz C, Markowska J, Molina R, Sturgeon C, Bowman A and Einarsson R. Prognostic significance of CA 125 and TPS levels after 3 chemotherapy courses in ovarian cancer patients. Gynecol Oncol 2000; 79: 444-450.","journal-title":"Gynecol Oncol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.ejogrb.2019.07.010","article-title":"Perioperative change in CA125 is an independent prognostic factor for improved clinical outcome in advanced ovarian cancer","volume":"240","author":"Timmermans","year":"2019","unstructured":"Timmermans M, Zwakman N, Sonke GS, Van de Vijver KK, Duk MJ, van der Aa MA and Kruitwagen RF. Perioperative change in CA125 is an independent prognostic factor for improved clinical outcome in advanced ovarian cancer. Eur J Obstet Gynecol Reprod Biol 2019; 240: 364-369.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"Li Z, Yin H, Ren M and Shen Y. Prognostic significance of CA125 dynamic change for progression free survival in patients with epithelial ovarian carcinoma. Med Sci Monit 2020; 26: e925051.","DOI":"10.12659\/MSM.925051"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1007\/s00404-018-4706-8","article-title":"Preoperative elevated platelet count and thrombocytosis in gynecologic malignancies","volume":"297","author":"Abu-Zaid","year":"2018","unstructured":"Abu-Zaid A, Alomar O, Al-Badawi IA and Salem H. Preoperative elevated platelet count and thrombocytosis in gynecologic malignancies. Arch Gynecol Obstet 2018; 297: 1071-1072.","journal-title":"Arch Gynecol Obstet"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s12885-016-2070-2","article-title":"Thrombocytosis and hyperfibrinogenemia are predictive factors of clinical outcomes in high-grade serous ovarian cancer patients","volume":"16","author":"Feng","year":"2016","unstructured":"Feng Z, Wen H, Bi R, Duan Y, Yang W and Wu X. Thrombocytosis and hyperfibrinogenemia are predictive factors of clinical outcomes in high-grade serous ovarian cancer patients. BMC Cancer 2016; 16: 43.","journal-title":"BMC Cancer"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1186\/s12885-016-2660-z","article-title":"Thresholds and timing of pre-operative thrombocytosis and ovarian cancer survival: analysis of laboratory measures from electronic medical records","volume":"16","author":"Cozzi","year":"2016","unstructured":"Cozzi GD, Samuel JM, Fromal JT, Keene S, Crispens MA, Khabele D and Beeghly-Fadiel A. Thresholds and timing of pre-operative thrombocytosis and ovarian cancer survival: analysis of laboratory measures from electronic medical records. BMC Cancer 2016; 16: 612.","journal-title":"BMC Cancer"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1056\/NEJMoa1110352","article-title":"Paraneoplastic thrombocytosis in ovarian cancer","volume":"366","author":"Stone","year":"2012","unstructured":"Stone RL, Nick AM, McNeish IA, Balkwill F, Han HD, Bottsford-Miller J, Rupairmoole R, Armaiz-Pena GN, Pecot CV, Coward J, Deavers MT, Vasquez HG, Urbauer D, Landen CN, Hu W, Gershenson H, Matsuo K, Shahzad MM, King ER, Tekedereli I, Ozpolat B, Ahn EH, Bond VK, Wang R, Drew AF, Gushiken F, Lamkin D, Collins K, DeGeest K, Lutgendorf SK, Chiu W, Lopez-Berestein G, Afshar-Kharghan V and Sood AK. Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med 2012; 366: 610-618.","journal-title":"N Engl J Med"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.ajpath.2015.11.011","article-title":"The dualistic model of ovarian carcinogenesis: revisited, revised, and expanded","volume":"186","author":"Kurman","year":"2016","unstructured":"Kurman RJ and Shih IeM. The dualistic model of ovarian carcinogenesis: revisited, revised, and expanded. Am J Pathol 2016; 186: 733-747.","journal-title":"Am J Pathol"}],"container-title":["American Journal of Cancer Research"],"original-title":[],"link":[{"URL":"https:\/\/e-century.us\/files\/ajcr\/15\/11\/ajcr0168689.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T02:38:45Z","timestamp":1768963125000},"score":1,"resource":{"primary":{"URL":"https:\/\/e-century.us\/files\/ajcr\/15\/11\/ajcr0168689.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":42,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.62347\/vngo9832","relation":{},"ISSN":["2156-6976"],"issn-type":[{"value":"2156-6976","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]}}}